ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year

Existing cash resources of $63.8M at quarter end are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial. “2026 has the potential to be a significant year for patients with Alzheimer’s disease and their caregivers,” said CEO Neil Warma. “We believe ProMIS is well-positioned with PMN310 as a potentially differentiated treatment for patients with early AD. We are coming off a productive quarter, having closed a transformational financing of up to $175M, including potential proceeds from warrant exercises, and have executed well on our Phase 1b clinical trial. Near-term data catalysts, including the blinded 6-month interim analysis, are anticipated in early Q3 2026, and could provide important insight into the potential of our lead drug candidate, PMN310… ProMIS expects to complete 12-month dosing for all patients by year-end and to report unblinded top-line results in early 2027, providing a comprehensive view of PMN310’s safety, biomarker, and clinical outcomes by treatment group, and an important clinical test of PMN310’s selective targeting approach.”